Identification of differential TADs between normal, primary, and metastatic colorectal cancer (CRC) tissues. (A) Proportions of differential TADs identified in normal versus primary tumor and normal versus metastatic tumor comparisons. (B) Proportions of differential and nondifferential TADs containing no DEGs or at least one DEG. Each point represents one patient pair. Statistical significance was assessed using a Wilcoxon signed-rank test: (**) P < 0.01, (NS) nonsignificant. (C) Overlap between differential TADs and CRC metastasis-associated genes in patients with and without metastasis. (D) A differential TAD in patient P05 overlapping a deletion and containing FHIT. (E) Proportions of SVs that overlapped differential TADs across eight normal versus primary tumor comparisons. Error bars indicate standard deviations. (F) Differential TADs and SVs in normal versus primary tumor and normal liver versus metastatic liver comparisons. (G,H) Differential TADs associated with DEGs in patient P02 for normal versus primary tumor and normal liver versus metastasis, respectively. (RPM) Reads per million. (I) GO enrichment of genes within comparison-specific differential TADs in patient P02.